A response from Nick Ede this afternoon:
The OASIS trial design is different to MAST. The current monotherapy dosing of CF33-CD19 onCARlytics is starting at a high dose, essentially 1 x E8 PFU per dose (9.54E7 PFU to be accurate). There is no dose escalation planned, although when we soon move to the combination phase of the trial, we will deescalate to 3 x E7 PFU before returning to 9.54E7 once safety at the one dose level down is confirmed. Hence the OASIS trial will deliver results much faster than MAST. We are very excited about 2024 and what it will deliver!
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient, page-71
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.3¢ | $255.7K | 18.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 65 | 18692454 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 4515891 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |